



## Letter to the Editor

## *Cryptosporidium* infections in Sweden—understanding the regional differences in reported incidence

Dear Sir,

Human cryptosporidiosis is an under-diagnosed gastrointestinal illness caused by protozoa of the genus *Cryptosporidium* [1]. The *Cryptosporidium* parasite is detected in stool samples by microscopy with modified acid-fast or fluorescent stains, via antigen detection, or nucleic acid amplification [2]. A total of 404 *Cryptosporidium* infections were notified in Sweden in 2014, but the incidence between counties varied from 0 to 34.44 per 100 000 inhabitants.


To understand the regional differences in reported incidence of *Cryptosporidium*, an on-line questionnaire regarding the laboratory methods and screening strategies used for *Cryptosporidium* was submitted in October 2015 to 26 clinical microbiological laboratories known to perform parasitological analyses in Sweden. All laboratories responded. Twenty-one laboratories perform *Cryptosporidium* diagnostics, whereas the remaining five laboratories refer their samples for testing elsewhere. Thirteen of the laboratories use the microscopy-based modified Ziehl–Neelsen staining method (mZN) after formol-ethyl acetate concentration, the currently recommended reference method in Sweden. Four laboratories use a multiplexed PCR including detection of *Cryptosporidium* and four laboratories use both methods (mZN and PCR). Five laboratories introduced PCR testing after October 2014. Laboratories use different algorithms for *Cryptosporidium* testing; two laboratories analyse all stool samples from patients with gastrointestinal symptoms regardless of request by PCR, 12 perform *Cryptosporidium* analysis on all stool samples referred with a parasite request (one with PCR; 11 by microscopy on formol-ethyl acetate concentrated wet-smears and then confirm the existence of *Cryptosporidium* oocysts with mZN) and the remaining six laboratories only analyse for *Cryptosporidium* if a clinician has specifically requested it (by mZN). Data were missing for one laboratory.

The calculated mean incidence of *Cryptosporidium* was significantly higher in Halland, Jönköping and Uppsala counties in 2014 (34.44 per 100 000 (95% CI 32.72–36.16), 21.40 per 100 000 (95% CI 20.33–22.47 and 15.01 per 100 000; (95% CI 14.26–15.76, respectively) than in the remaining 18 counties (2.00 per 100 000; (95% CI 1.90–2.10);  $p$  0.006 by a non-parametric Kruskal–Wallis test, Fig. 1). The same was observed in 2015. These incidences were higher than previously reported from Europe [3]. These counties all analyse a broad range of faecal samples for *Cryptosporidium* either by PCR or microscopy. Uppsala and Jönköping counties analyse all stool samples referred with parasite request for

*Cryptosporidium*, whereas Halland county analyses all diarrhoeal stool samples. In these counties, the positivity rates varied from 1.3% (Uppsala; 62/4941; 95% CI 1.2–1.4) and 1.6% (Jönköping; 115/7140; 95% CI 1.5–1.7) to 2.3% (Halland; 123/5391; 95% CI 2.2–2.4) in 2014. A previous English study identified a positivity rate of 0.6% for laboratories testing all stool samples for *Cryptosporidium*, but the method used was not analysed [4]. The incidence was lower in those counties referring the samples elsewhere for testing or analysing samples only upon a specific *Cryptosporidium* request. It is of concern that several laboratories state that they screen wet smears for *Cryptosporidium* as a routine procedure, but report very low numbers of cases. *Cryptosporidium* oocysts are very small and difficult to detect reliably by wet smears without mZN staining; screening wet smears is not recommended for *Cryptosporidium* diagnosis [1,2]. However, the laboratory in Jönköping is distinct from the other laboratories—despite using the wet smear screen approach they find a large number of cases, which is probably due to experienced and well-trained staff. The possibility that the variation in incidence between counties is due to reasons other than diagnostic procedures was not addressed here.

Based on the assumption that the incidences obtained in Halland, Uppsala and Jönköping counties for 2014–2015 are more accurate than currently reported numbers from counties with lower incidences, a national incidence was calculated. It was much higher than currently reported (22.85 (95% CI 21.70–23.99) versus 5.47 (95% CI 5.20–5.74)). Furthermore, according to our estimations, over 2000 *Cryptosporidium* infections would have been diagnosed in Sweden in 2014 (or 2015) if all diarrhoeal stool samples submitted with a parasite request had been properly tested for *Cryptosporidium*. This is over four times more than currently reported. Moreover, these are the estimated figures of diagnosed cases still constituting only a minority of total cases as most patients might not seek healthcare or are not properly sampled.

Molecular techniques including PCR clearly provide an improved workflow enabling more testing; some studies have also demonstrated their improved sensitivity for detection of *Cryptosporidium* compared with mZN [2,5]. Microscopy, on the other hand, has the advantage of being a non-selective method that detects all parasites present in the sample. It is an alternative method reaching comparable sensitivity to PCR but only if combined with appropriate staining and trained laboratory personnel. How the expertise in the field of parasite morphology can be maintained within the high-throughput microbiological laboratories needs to be discussed further. However, analysing a broad range of faecal



**Fig. 1.** Each dot represents an incidence of *Cryptosporidium* per 100 000 people within a single county. The calculated mean incidence of *Cryptosporidium* in the 18 Swedish counties (Region A) in comparison with the mean incidence in the Uppsala, Halland and Jönköping counties (Region B) in 2014 and 2015. One county has been marked with a grey dot; they introduced PCR-based screening including *Cryptosporidium* of all faecal samples in June 2015.

samples with an adequate method for *Cryptosporidium* can be of public health significance. Correct diagnosis is not only important for the patient but also helps to prevent secondary transmissions and outbreaks.

In conclusion, the variation observed in the incidence of *Cryptosporidium* across the Swedish counties reflected both variation in detection methods used and variation in testing algorithms applied. When interpreting the incidence of *Cryptosporidium* at national and international level, it is important to be aware of the impact of different diagnostic methods and testing algorithms used on the number of diagnosed cases as a potential artefact behind reported regional differences.

#### Acknowledgements

We are grateful to all Swedish Clinical Microbiological Laboratories for efficient collaboration and providing detailed data. We would also like to thank Aftab Jasir, European Centre for Disease Control, for input to the project proposal and follow up of the work, and Drs Marianne Lebbad and Karin Tegmark Wisell for reviewing this manuscript. This work has been constructed as a part of the collaborative project between the National Veterinary Agency, the Public Health Agency of Sweden and the National Food Agency, entitled 'Capacity assessment of surveillance system in use for the six most important zoonoses'; we would like to thank Cecilia Jernberg for the opportunity to participate in this project.

#### Funding

This work was supported by the European Centre for Disease Control; Heli Harvala has been funded by the European Program for Public Health Microbiology Training Fellowship. This work has been constructed as a part of a collaborative project between the National Veterinary Agency, the Public Health Agency of Sweden and the National Food Agency, funded by the Swedish Civil Contingencies Agency (MSB).

#### Transparency declaration

The authors have reported no conflicts of interest.

#### References

- [1] Cacció SM, Chalmers RM. Human cryptosporidiosis in Europe. *Clin Microbiol Infect* 2016;22:471–80.
- [2] Checkley W, White Jr AC, Jaganath D, Arrowood MJ, Chalmers RM, Chen XM, et al. A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium. *Lancet Infect Dis* 2015;15:85–94.
- [3] European Centre for Disease Prevention and Control. Annual epidemiological report 2014 – food- and waterborne diseases and zoonoses. Stockholm: ECDC; 2014.
- [4] Chalmers RM, Atchison C, Barlow K, Young Y, Roche A, Manuel R. An audit of the laboratory diagnosis of cryptosporidiosis in England and Wales. *J Med Microbiol* 2015;64:688–93.
- [5] Bruijnesteijn van Coppenraet LE, Wallinga JA, Ruijs GJ, Bruins MJ, Verweij. Parasitological diagnosis combining an internally controlled real-time PCR assay for the detection of four protozoa in stool samples with a testing algorithm for microscopy. *Clin Microbiol Infect* 2009;15:869–74.

H. Harvala

Public Health Agency of Sweden, Solna, Sweden

European Programme for Public Health Microbiology Training (EUPHEM), European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden

J. Ögren

Microbiology Laboratory, Division of Medical Diagnostics, Jönköping, Sweden

P. Boman

Clinical Microbiology, Uppsala University Hospital, Uppsala, Sweden

H.M. Riedel

Clinical Microbiology, Uppsala University Hospital, Uppsala, Sweden

Department of Medical Sciences, Section of Clinical Bacteriology, Uppsala University, Uppsala, Sweden

P. Nilsson

Department of Clinical Microbiology, Halland County Hospital, Halmstad, Sweden

J. Winiecka-Krusnell

Public Health Agency of Sweden, Solna, Sweden

J. Beser\*

Public Health Agency of Sweden, Solna, Sweden

\* Corresponding author.

E-mail address: [jessica.beser@folkhalsomyndigheten.se](mailto:jessica.beser@folkhalsomyndigheten.se) (J. Beser).

10 August 2016

Available online 23 September 2016

Editor: L. Leibovici